Antidepressants for prevention of severe COVID-19, Long COVID and outlook for other viral diseases
26th treatment shown to reduce risk in
November 2021 *, now known with p = 0.00014 from 21 studies, recognized in 3 countries.
|
Review of clinical studies on the potential benefits of antidepressants for prevention and treatment of COVID-19 and its sequelae. Authors summarize evidence from retrospective studies, randomized controlled trials, prospective studies, and meta-analyses suggesting that antidepressants, especially selective serotonin reuptake inhibitors and serotonin-norepinephrine reuptake inhibitors, may help prevent SARS-CoV-2 infection, reduce COVID-19 severity and mortality, and potentially alleviate long COVID symptoms. Proposed mechanisms include direct antiviral effects and anti-inflammatory properties. Authors make a case for considering inexpensive and available antidepressants as adjunctive therapy, emphasizing their affordability and availability.
Bonnet et al., 20 Feb 2024, peer-reviewed, 3 authors.
Abstract: TYPE Opinion
PUBLISHED 20 February 2024
DOI 10.3389/fmed.2024.1305184
OPEN ACCESS
EDITED BY
Daniel Diaz,
National Autonomous University of
Mexico, Mexico
REVIEWED BY
Velyn Wu,
University of Florida, United States
*CORRESPONDENCE
Udo Bonnet
udo.bonnet@uni-due.de
RECEIVED 17 December 2023
ACCEPTED 05 February 2024
PUBLISHED 20 February 2024
CITATION
Bonnet U, Juckel G and Kuhn J (2024)
Antidepressants for prevention of severe
COVID-19, Long COVID and outlook for other
viral diseases. Front. Med. 11:1305184.
doi: 10.3389/fmed.2024.1305184
Antidepressants for prevention of
severe COVID-19, Long COVID
and outlook for other viral
diseases
Udo Bonnet1,2*, Georg Juckel3 and Jens Kuhn4,5
1
Department of Mental Health, Evangelisches Krankenhaus Castrop-Rauxel, Academic Teaching
Hospital of the University of Duisburg/Essen, Castrop-Rauxel, Germany, 2 Department of Psychiatry
and Psychotherapy, Faculty of Medicine, Landschaftsverband Rheinland-Hospital Essen, University of
Duisburg-Essen, Essen, Germany, 3 Department of Psychiatry, Psychotherapy and Preventive Medicine,
LWL University Hospital, Ruhr University Bochum, Bochum, Germany, 4 Department of Psychiatry and
Psychotherapy, University Hospital Cologne, Cologne, Germany, 5 Alexianer Hospital Cologne,
Cologne, Germany
KEYWORDS
antidepressants, resilience, prevention, COVID-19, Long COVID, Post COVID, PACS
COPYRIGHT
© 2024 Bonnet, Juckel and Kuhn. This is an
open-access article distributed under the
terms of the Creative Commons Attribution
License (CC BY). The use, distribution or
reproduction in other forums is permitted,
provided the original author(s) and the
copyright owner(s) are credited and that the
original publication in this journal is cited, in
accordance with accepted academic practice.
No use, distribution or reproduction is
permitted which does not comply with these
terms.
Please send us corrections, updates, or comments.
c19early involves the extraction of 100,000+ datapoints from
thousands of papers.
Community updates
help ensure high accuracy.
Treatments and other interventions are complementary.
All practical, effective, and safe
means should be used based on risk/benefit analysis.
No treatment or intervention is 100% available and effective for all current
and future variants.
We do not provide medical advice. Before taking any medication,
consult a qualified physician who can provide personalized advice and details
of risks and benefits based on your medical history and situation.
FLCCC and
WCH
provide treatment protocols.
Submit
